… commercially-insured population of NVAF patients with obesity and polypharmacy in the US.
… treatment option for NVAF patients with obesity and polypharmacy compared to warfarin. …

… of both obesity and polypharmacy in NVAF patients, this … of NVAF patients with both obesity
and polypharmacy. The … bleeding overall among NVAF patients with obesity and one or …

… The results of the present study build upon prior findings in NVAF patients with obesity
irrespective of polypharmacy status [49,50]. In a recent study by the present authors [50], …

… This study compared the risk of stroke/systemic embolism (SE) and major bleeding (MB)
among NVAF patients with polypharmacy newly prescribed oral anticoagulants (OACs). …

… This claims-based study was extended to evaluate HRU and costs for patients with NVAF,
obesity, and polypharmacy (defined as five or more concurrent outpatient prescriptions) [48]. …

… or thrombotic outcomes for severely obese patients with NVAF taking Factor Xa Inhibitors …
of Factor Xa Inhibitors as an alternative to warfarin in severely obese patients with NVAF. …

… , in patients receiving warfarin.7 Due to the high likelihood of polypharmacy in patients with
NVAF and … in patients with NVAF managed in routine clinical practice with varying degrees of …

… the use of DOACs in non-obese patients with cancer-related … in this specific subpopulation
when obesity is present. Simi… indicates benefits of DOACs in patients with renal disease [57…

… healthcare costs compared to warfarin among complex patients with comorbid conditions
such as obesity [33,34,35], as well as those with concurrent NVAF, obesity, and diabetes [36]. …

… NVAF patients have a fivefold increased risk of … Polypharmacy and the efficacy and safety
of rivaroxaban versus … versus warfarin in obese nonvalvular atrial fibrillation patients: analysis …